Oramed, Medpace collaborate for oral insulin phase II clinical trial
The FDA-approved trial will examine the safety and efficacy of ORMD-0801 in 147 patients at multiple centers across the US. Oramed is expected to commence the trial after
The US Food and Drug Administration (FDA) has approved AstraZeneca’s Imfinzi (durvalumab) in combination with Padcev (enfortumab vedotin) for adult patients with muscle-invasive bladder cancer (MIBC) who cannot receive or have refused cisplatin-based chemotherapy.